KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $48,289,720 | -20.7% | 1,514,734 | 0.0% | 1.03% | -7.0% |
| Q2 2023 | $60,862,012 | -15.1% | 1,514,734 | -9.8% | 1.10% | -21.7% |
| Q1 2023 | $71,711,106 | -11.1% | 1,679,417 | 0.0% | 1.41% | -8.7% |
| Q4 2022 | $80,645,604 | +27.6% | 1,679,417 | 0.0% | 1.54% | +31.5% |
| Q3 2022 | $63,180,000 | +36.2% | 1,679,417 | 0.0% | 1.17% | +39.5% |
| Q2 2022 | $46,402,000 | -49.2% | 1,679,417 | 0.0% | 0.84% | -43.2% |
| Q1 2022 | $91,327,000 | -7.1% | 1,679,417 | 0.0% | 1.48% | +17.3% |
| Q4 2021 | $98,263,000 | +47.9% | 1,679,417 | 0.0% | 1.26% | +73.0% |
| Q3 2021 | $66,438,000 | -6.9% | 1,679,417 | 0.0% | 0.73% | +1.2% |
| Q2 2021 | $71,325,000 | -31.0% | 1,679,417 | 0.0% | 0.72% | -25.4% |
| Q1 2021 | $103,368,000 | -12.7% | 1,679,417 | 0.0% | 0.97% | -6.8% |
| Q4 2020 | $118,466,000 | +82.9% | 1,679,417 | 0.0% | 1.04% | +27.4% |
| Q3 2020 | $64,775,000 | +2.8% | 1,679,417 | 0.0% | 0.81% | -8.2% |
| Q2 2020 | $62,995,000 | – | 1,679,417 | – | 0.89% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,382,641 | $85,102,000 | 10.19% |
| Consonance Capital Management LP | 890,209 | $54,792,000 | 5.84% |
| CHI Advisors LLC | 400,468 | $24,649,000 | 4.94% |
| Fairmount Funds Management LLC | 109,333 | $6,729,000 | 2.84% |
| VR Adviser, LLC | 372,306 | $22,915,000 | 2.49% |
| Opaleye Management Inc. | 157,500 | $9,694,000 | 1.42% |
| Darwin Global Management, Ltd. | 86,887 | $5,348,000 | 1.05% |
| Orbimed Advisors | 1,679,417 | $103,368,000 | 0.97% |
| Nantahala Capital Management | 460,372 | $28,336,000 | 0.83% |
| Eventide Asset Management | 427,414 | $26,307,000 | 0.39% |